APA (7th ed.) Citation

Hammad, H., Shaaban, A., Philips, M. V., Fayed, A., & Abdelaziz, T. S. (2023). Effect of sodium–glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: A pilot superiority randomized controlled trial. International urology and nephrology, 55(9), 2321-2326. https://doi.org/10.1007/s11255-023-03539-8

Chicago Style (17th ed.) Citation

Hammad, Hany, Asmaa Shaaban, Mariana Victor Philips, Ahmed Fayed, and Tarek Samy Abdelaziz. "Effect of Sodium–glucose Transporter 2 Inhibitor Empagliflozin on Proteinuria and Kidney Function Progression in Patients with Non-diabetic Glomerulonephritis: A Pilot Superiority Randomized Controlled Trial." International Urology and Nephrology 55, no. 9 (2023): 2321-2326. https://doi.org/10.1007/s11255-023-03539-8.

MLA (9th ed.) Citation

Hammad, Hany, et al. "Effect of Sodium–glucose Transporter 2 Inhibitor Empagliflozin on Proteinuria and Kidney Function Progression in Patients with Non-diabetic Glomerulonephritis: A Pilot Superiority Randomized Controlled Trial." International Urology and Nephrology, vol. 55, no. 9, 2023, pp. 2321-2326, https://doi.org/10.1007/s11255-023-03539-8.